ETV6 is a transcriptional repressor that binds DNA sequence 5'-CCGGAAGT-3' and plays critical roles in hematopoiesis and cell fate determination 1. In normal development, ETV6 controls monocyte differentiation into dendritic cells by repressing macrophage fate commitment through direct inhibition of MAFB expression 1. ETV6 also suppresses enhancer activity of GGAA microsatellite repeats, preventing aberrant oncogene activation 2. ETV6 is frequently involved in cancer-associated translocations. The ETV6-RUNX1 fusion, the most common in childhood acute lymphoblastic leukemia (ALL), functions through competition for RUNX1 binding sites and transcriptional repression, antagonizing RUNX1-mediated cell cycle regulation 3. ETV6-RUNX1 ALL demonstrates molecular heterogeneity with distinct transcriptomic subtypes showing divergent drug responses linked to PAX5 alterations 4. Other ETV6 fusions include ETV6-NTRK3 in mammary analogue secretory carcinoma 5 and ETV6-ACSL6 in myeloid neoplasms, where translocated super-enhancers activate inflammatory factor genes like IL-3, causing severe eosinophilia and poor prognosis 67. These fusion-driven mechanisms identify ETV6 as a key oncogenic driver and potential therapeutic target in hematopoietic malignancies.